Voyager Therapeutics Inc

NASDAQ:VYGR   3:59:50 PM EDT
5.93
+0.39 (+7.04%)
Earnings Announcements

Voyager Therapeutics Reports Third Quarter Financial And Operating Results

Published: 11/08/2022 12:43 GMT
Voyager Therapeutics Inc (VYGR) - Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results.
Voyager Therapeutics - Sees Cash, Cash Equivalents, Reimbursement for Development Costs Under Neurocrine Deal Sufficient to Meet Expenses Into 2024.
Beyond Neurocrine, Runway Could Improve Further Based on Potential Future Milestones in 2023 From Existing Collaborations.
Qtrly Net Income per Share, Diluted $ 0.45.
Q3 Earnings per Share View $-0.32 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $2.02 Million
Adjusted EPS is expected to be -$0.59

Next Quarter Revenue Guidance is expected to be $4.37 Million
Next Quarter EPS Guidance is expected to be -$0.54

More details on our Analysts Page.